876063-40-0

Basic information

• Product Name: ETHYL (4-CYCLOPROPYLSULFONYLPHENYL)OXOACETATE
• Synonyms: ETHYL (4-CYCLOPROPYLSULFONYLPHENYL)OXOACETATE;[4-(Cyclopropylsulfonyl)phenyl](oxo)acetic acid ethyl ester;Ethyl 2-[4-(cyclopropylsulfonyl)phenyl]-2-oxoacetate;(4-Cyclopropanesulfonyl-phenyl)-oxo-acetic acid ethyl ester;Benzeneacetic acid, 4-(cyclopropylsulfonyl)-α-oxo-, ethyl ester
• CAS NO: 876063-40-0
• Molecular Formula: C₁₃H₁₄O₅S
• Molecular Weight: 282.31
• Mol File: 876063-40-0.mol

Chemical Properties

• Appearance: /
• Density: 1.353
• CAS DataBase Reference: ETHYL (4-CYCLOPROPYLSULFONYLPHENYL)OXOACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL (4-CYCLOPROPYLSULFONYLPHENYL)OXOACETATE(876063-40-0)
• EPA Substance Registry System: ETHYL (4-CYCLOPROPYLSULFONYLPHENYL)OXOACETATE(876063-40-0)

Safety Data

• Hazardous Substances Data: 876063-40-0(Hazardous Substances Data)

Upstream product

• 745052-94-2 ethyl 2-(4-cyclopropylsulfanylphenyl)-2-oxoacetate 
• 14633-54-6 cyclopropylphenylsulfide 

Downstream Products

• 745052-95-3 ethyl 2-(4-(cyclopropylthio)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 745052-96-4 ethyl 2-(4-(cyclopropylsulfonyl)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 1039020-73-9 C₁₁H₁₀O₅S 
• 1313812-55-3 (4-cyclopropylsulfonyl)phenyl-oxo-acetic acid ethyl ester p-toluene sulfonyl hydrazone 
• 745052-98-6 (E)-2-(4-(cyclopropylsulfonyl)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylic acid 
• 1234703-41-3 (4-cyclopropanesulfonyl-phenyl)-diazo-acetic acid ethyl ester 
• 1313812-56-4 (4-cyclopropanesulfonyl-phenyl)-[(tetrahydro-pyran-4-yloxy)]-acetic acid ethyl ester 
• 1328998-23-7 (4-cyclopropanesulfonyl-phenyl)-[(tetrahydro-furan-3-yloxy)]-acetic acid ethyl ester 
• 1328998-24-8 (4-cyclopropanesulfonyl-phenyl)-[(tetrahydro-furan-3-yloxy)]-acetic acid 
• 1328998-27-1 (4-cyclopropanesulfonyl-phenyl)-[(tetrahydro-pyran-4-yloxy)]-acetic acid 
• 1328983-39-6 4-{2-[2-(4-Cyclopropanesulfonyl-phenyl)-2-(tetrahydro-pyran-4-yloxy)-acetylamino]-thiazol-5-yloxy}-benzoic acid methyl ester 
• 1359153-10-8 cyclopentyloxy-(4-cyclopropanesulfonyl-phenyl)-acetic acid ethyl ester 
• 1359151-08-8 4-{2-[2-cyclopentyloxy-2-(4-cyclopropanesulfonyl-phenyl)-acetylamino]-thiazol-5-yloxy}-benzoic acid 
• 1359150-63-2 4-{2-[2-cyclopentyloxy-2-(4-cyclopropanesulfonyl-phenyl)-acetylamino]-thiazol-5-yloxy}-benzoic acid methyl ester 

Relevant articles and documents

Acetamide compounds as glucokinase activators, their process and medicinal applications

Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or m

ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION

This disclosure relates to a series of acetamide compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof. The disclosure also relates to process of preparation of

ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION

Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or m

CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-4-YL)-PROPIONAMIDE

Crystalline R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide and methods of its preparation and use are disclosed.

SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: Discovery of PSN-GK1

Allosteric activators of the glucose-sensing enzyme glucokinase (GK) are currently attracting much interest as potential antidiabetic therapies because they can achieve powerful blood glucose lowering through actions in multiple organs. Here, the optimization of a weakly active high-throughput screening hit to (2R)-2-(4-cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide (PSN-GK1), a potent GK activator with an improved pharmacokinetic and safety profile, is described. Following oral administration, this compound elicited robust glucose lowering in rats.

TRICYCLO SUBSTITUTED AMIDES

Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

ENANTIOSELECTIVE PROCESS

A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives.

FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE

A process for the production of fluorinated compound formula (I) comprising fluorination of a protected aminothiazole. Compounds formula (I) are useful in the preparation of activators of glucokinase.